BACKGROUND: Although cytoreductive surgery and intraperitoneal chemotherapy have been advocated as standard treatment for @entity2466 with isolated peritoneal @entity3 , the optimal method of chemotherapy administration has not been established. At our institution, @entity1 undergoing complete cytoreduction in this setting typically receive multiple cycles of early postoperative intraperitoneal chemotherapy. OBJECTIVES: The aim of this study was to describe @entity1 with @entity3906 treated with complete cytoreductive surgery and early postoperative intraperitoneal chemotherapy and to document associated time to progression and morbidity. DESIGN: This is a retrospective study at a single specialty institution. Hospital and departmental databases were searched for @entity1 presenting with primary @entity2466 undergoing cytoreductive surgery, placement of intraperitoneal port, and subsequent intraperitoneal chemotherapy from June 1995 to September 2009. SETTINGS: This study was conducted at Memorial Sloan-Kettering Cancer Center. @entity1 : We identified 50 @entity1 (30 female), median age 48 (range, 26-66) who met the criteria. INTERVENTIONS: Cytoreductive surgery, placement intraperitoneal port, and intraperitoneal chemotherapy were performed. RESULTS: All @entity1 underwent intraperitoneal catheter placement after complete cytoreductive surgery, followed by a median of 4 cycles (range, 1-9) intraperitoneal @entity10928 (1000 mg/m daily for 3 days) plus @entity4181 (240 mg/m). The median hospital length of stay was 9 days (maximum, 29). Thirty-four percent of the @entity1 experienced complications; 12% experienced major complications (3 abdominal abscesses, 1 @entity1150 , 1 abdominal @entity548 , and 1 intraperitoneal port malfunction). There were no 30-day mortalities. Five-year recurrence-free interval was observed in 43%. Among 23 @entity1 with recurrence, 18 had a recurrence only within the peritoneum. The median overall survival was 9.8 years. LIMITATIONS: This is a retrospective study. Many @entity1 had surgery first at other institutions; therefore, pathologic examination of resected material was not possible in every case. Other factors possibly impacting time to recurrence (ie, preoperative chemotherapy, duration between onset of disease and presentation to our institution) varied among @entity1 and were not controlled for. In the absence of a control arm undergoing complete cytoreduction without early postoperative intraperitoneal chemotherapy, we did not ascertain whether intraperitoneal chemotherapy confers additional benefit. CONCLUSIONS: Cytoreductive surgery plus multiple cycles of early postoperative intraperitoneal chemotherapy is safe, achieving survival results similar to published outcomes of other protocols (including hyperthermic intraperitoneal chemotherapy). Prospective trials are warranted to compare various methods of intraperitoneal chemotherapy in this setting.

Early postoperative intraperitoneal chemotherapy following cytoreductive surgery for appendiceal mucinous neoplasms with isolated peritoneal XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity4181 :: ('MESH:D002955', 'Chemical') :: ['leucovorin'] @entity2466 :: ('MESH:D001063', 'Disease') :: ['appendiceal neoplasms'] @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage'] @entity10928 :: ('MESH:C576827', 'Chemical') :: ["5-fluoro-2'-deoxyuridine"] @entity3906 :: ('MESH:D010534', 'Disease') :: ['appendiceal neoplasms and peritoneal dissemination'] @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep vein thrombosis'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']
@entity3 :: (MESH:D009362,Disease) :: ['metastasis']
